The functional characterisation of IL‐25, IL‐33 and TSLP in the outset of the cutaneous inflammation has led to the development of biologics targeting each cytokine or their cognate receptor for AD and indeed other allergic disorders. This evidence concerns the gene IL33 and Alzheimer disease.